Jan 25, 2023 / 12:00PM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Torrent Pharmaceuticals Q3 FY '23 Earnings Conference Call. (Operator Instructions)
I now hand the conference over to Mr. Sudhir Menon.
Sudhir Menon - Torrent Pharmaceuticals Limited - Executive Director of Finance & CFO
Thank you. Good evening, and welcome to quarter 3 FY '23 earnings call. Quarter 3 registered revenue growth of 18%, led by strong growth in the branded generic markets and steady performance of the generic markets. Branded generic markets constituted 70% of the total revenue base. The growth in the branded generic markets were primarily driven by new launch momentum, performance of the top brands and integration of acquired portfolio.
In terms of financial performance during the quarter, the revenues were INR 2,491 crores, up by 18% on Y-o-Y basis. Operating EBITDA was INR 724 crores with operating EBITDA margins at 29.1%. There is a one-off impact on gross margins by around 0.6% for the quarter due to under absorption of manufacturing cost as there was a temporary
Q3 2023 Torrent Pharmaceuticals Ltd Earnings Call Transcript
Mar 19, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers